BioNova Pharma Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • BioNova Pharma's estimated annual revenue is currently $3.4M per year.(i)
  • BioNova Pharma's estimated revenue per employee is $201,000

Employee Data

  • BioNova Pharma has 17 Employees.(i)
  • BioNova Pharma grew their employee count by 6% last year.

BioNova Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is BioNova Pharma?

BioNova Pharmaceuticals Ltd is an innovative biotech company engaged primarily in the discovery, development and commercialization of breakthrough therapies for the treatment of diseases with high unmet medical need, with a focus on the Greater China market Our talent, scientific knowledge and research capabilities help us accelerate drug development in China and bring innovative medicines to the Chinese patients

keywords:N/A

N/A

Total Funding

17

Number of Employees

$3.4M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BioNova Pharma News

2022-04-13 - Asahi Kasei To Acquire Bionova Scientific

Bionova Scientific is a portfolio company of Great Point Partners, a Greenwich, CT-based private investment firm focused exclusively on the...

2022-04-13 - Asahi Kasei Medical agrees to buy Bionova Scientific

In 2019, Asahi Kasei Group agreed to acquire Danish pharma company Veloxis Pharmaceuticals through its Danish subsidiary Asahi Kasei Pharma...

2022-04-13 - Asahi Kasei scoops up CDMO Bionova, bolstering its antibody ...

Now, the British pharma giant has gotten a taste of what that rebound will look like—even though CEO Emma Walmsley still warns of speed bumps ahead. Shingrix...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M17-23%N/A
#2
$1.5M17N/AN/A
#3
$1.5M17N/AN/A
#4
$1.5M17N/AN/A
#5
$1.5M17N/AN/A